Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bassem Yamout

Showing results (41-50 of 81) with videos related to

Pageof 9
Sort By:
Multiple Sclerosis and Related Disorders|December 11, 2025
Expert consensus on the clinical use of cladribine tablets for treating relapsing multiple sclerosis in the asia-pacific regionHo Jin Kim, Suzanne J Hodgkinson, Long-Sun Ro, et al.
Journal of the Neurological Sciences|January 22, 2026
Directions for advancing prognostic assessments in multiple sclerosis: Qualitative Insights from MS specialist InterviewsSofie Aerts, Lotte Geys, Deborah Severijns, et al.
Multiple Sclerosis and Related Disorders|August 9, 2024
Disease-modifying therapies, outcomes, risk factors and severity of COVID-19 in multiple sclerosis: A MENACTRIMS registry based studyMaya Zeineddine, Amal Al-Hajje, Pascale Salameh, et al.
Neurology and Therapy|August 3, 2024
Practical Recommendations from the Gulf Region on the Therapeutic Use of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis: Impact of the Latest Real-World Evidence on Clinical PracticeBassem Yamout, Raed Alroughani, Jihad Inshasi, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 19, 2024
Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase RegistryAlessio Signori, Marta Ponzano, Tomas Kalincik, et al.
CNS Drugs|January 27, 2026
Consensus Recommendations for the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD): The MENACTRIMS GuidelinesBassem Yamout, Riadh Gouider, Raed Al-Roughani, et al.
The Lancet. Neurology|February 21, 2026
Current evidence and knowledge gaps in family planning and pregnancy in myasthenia gravis, NMOSD, and MOGADDalia L Rotstein, Raed Alroughani, Georgina Arrambide, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 26, 2024
Safety and effectiveness of disease-modifying therapies after switching from natalizumabMaya Zeineddine, Raed Al-Roughani, Samar Farouk Ahmed, et al.
Neurology. Clinical Practice|May 1, 2018
Effectiveness of alternative dose fingolimod for multiple sclerosisErin E Longbrake, Daniel Kantor, Siddharama Pawate, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 1, 2025
Comparative effectiveness of natalizumab and anti-CD20 monoclonal antibodies in relapsing-remitting multiple sclerosis: a real-world propensity-score matched studyBassem Yamout, Raed Alroughani, Samar Frouk Ahmed Mohamed, et al.
Pageof 9

Showing results (41-50 of 81) with videos related to

Sort By:
Pageof 9
Multiple Sclerosis and Related Disorders|December 11, 2025
Expert consensus on the clinical use of cladribine tablets for treating relapsing multiple sclerosis in the asia-pacific regionHo Jin Kim, Suzanne J Hodgkinson, Long-Sun Ro, et al.
Journal of the Neurological Sciences|January 22, 2026
Directions for advancing prognostic assessments in multiple sclerosis: Qualitative Insights from MS specialist InterviewsSofie Aerts, Lotte Geys, Deborah Severijns, et al.
Multiple Sclerosis and Related Disorders|August 9, 2024
Disease-modifying therapies, outcomes, risk factors and severity of COVID-19 in multiple sclerosis: A MENACTRIMS registry based studyMaya Zeineddine, Amal Al-Hajje, Pascale Salameh, et al.
Neurology and Therapy|August 3, 2024
Practical Recommendations from the Gulf Region on the Therapeutic Use of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis: Impact of the Latest Real-World Evidence on Clinical PracticeBassem Yamout, Raed Alroughani, Jihad Inshasi, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 19, 2024
Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase RegistryAlessio Signori, Marta Ponzano, Tomas Kalincik, et al.
CNS Drugs|January 27, 2026
Consensus Recommendations for the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD): The MENACTRIMS GuidelinesBassem Yamout, Riadh Gouider, Raed Al-Roughani, et al.
The Lancet. Neurology|February 21, 2026
Current evidence and knowledge gaps in family planning and pregnancy in myasthenia gravis, NMOSD, and MOGADDalia L Rotstein, Raed Alroughani, Georgina Arrambide, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 26, 2024
Safety and effectiveness of disease-modifying therapies after switching from natalizumabMaya Zeineddine, Raed Al-Roughani, Samar Farouk Ahmed, et al.
Neurology. Clinical Practice|May 1, 2018
Effectiveness of alternative dose fingolimod for multiple sclerosisErin E Longbrake, Daniel Kantor, Siddharama Pawate, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 1, 2025
Comparative effectiveness of natalizumab and anti-CD20 monoclonal antibodies in relapsing-remitting multiple sclerosis: a real-world propensity-score matched studyBassem Yamout, Raed Alroughani, Samar Frouk Ahmed Mohamed, et al.
Pageof 9